Topical TreatmentOnce a Day Topical Treatment for Athlete's Foot Fungus Inbetween the Toes in Males and Females

Inclusion Criteria:

1. Males and females 18 years of age and over.
2. Women of child bearing age must have a negative urine pregnancy test at Day 0 (baseline) and Day 42 (visit 6) or at the discontinuation visit and must agree to use an acceptable method of contraception during the study.
3. Subjects must have clinical evidence of interdigital tinea pedis of one or both feet characterized by: moderate erythema and scaling and mild pruritis.
4. The clinical diagnosis must be confirmed by a positive KOH preparation, where fungal elements are visible from a skin scraping of the interdigital area of the feet.
5. Fungal cultures obtained at the baseline visit must be positive by day 14 for the subject to remain in the study.
6. All non-study medications not specifically excluded by this protocol may be continued.
7. All chronic diseases must be stable for at least one month.
8. Acute illnesses must be stabilized before enrollment.
9. The subject must be able to understand what is required, read and sign the informed consent, comply with the requirements of this study and adhere to the visit schedule.

Exclusion Criteria:

1. Under 18 years of age.
2. Pregnant or lactating females.
3. Treatment of sertaconazole or an investigational drug within the last 30 days prior to study enrollment.
4. No medications or emollients or foot powders or treatments other than those used in the study are to be applied to the treatment areas.
5. The following medications may not be used during the study:

• Oral anti-fungals 3 months prior to enrollment
• Topical anti-fungals to the feet 14 days prior to enrollment
• Systemic antibiotic or corticosteroid 30 days prior to enrollment
• Topical corticosteroid 30 days prior to enrollment
• Use of radiation therapy and/or anti-neoplastic agents within1 year of enrollment

6. Widespread dermatophytosis: moccasin tinea pedis, onychomycosis, oral, vaginal or chronic mucocutaneous candidiasis, bacterial skin infection.
7. Subject who are known or suspected to be immunocompromised.
8. Known sensitivity to any components of the test medication or hypersensitivity to imidazoles.
9. Any disease or condition that may compromise the evaluation of the therapeutic response of tinea pedis to treatment.
10. History of drug or alcohol dependency in the last 6 months.
11. History of atopic or contact dermatitis on the feet.
12. Unstable diabetes mellitus.
13. Subjects who have participated in any previous clinical trial of sertaconazole.
14. Subjects who cannot or will not sign the informed consent.